PU139|cas:158093-65-3|西域试剂

PU139,99.14%

产品编号：Bellancom-124696| CAS NO：158093-65-3| 分子式：C₁₂H₇FN₂OS| 分子量：246.26

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124696	￥1500.00	杭州北京（现货）
Bellancom-124696	￥2600.00	杭州北京（现货）
Bellancom-124696	￥5600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PU139

产品介绍

PU139 是一种有效的泛组蛋白乙酰转移酶 (HAT) 抑制剂。PU139 阻断 HATs Gcn5、p300/CBP 相关因子 (PCAF)、CBP 和 p300，IC₅₀ 分别为 8.39、9.74、2.49 和 5.35 μM。

生物活性

PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.

体外研究

PU139 inhibits cell growth with GI₅₀s of <60 μM (A431, A549, A2780, HepG2, SW480, U-87 MG, HCT116 and SK-N-SH and MCF7 cells).
PU139 (0-100 μM; 24-72 hours) triggers caspase-independent cell death in the neuroblastoma cell line SK-N-SH.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male NMRI:nu/nu mice (Neuroblastoma xenografts)
Dosage:	25 mg/kg
Administration:	Intraperitoneally (PU139) with Dxorubicin at 8 mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1 h.
Result:	Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings.

体内研究

PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male NMRI:nu/nu mice (Neuroblastoma xenografts)
Dosage:	25 mg/kg
Administration:	Intraperitoneally (PU139) with Dxorubicin at 8 mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1 h.
Result:	Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings.

性状

Solid

溶解性数据

In Vitro:

DMSO : 10 mg/mL (40.61 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0607 mL	20.3037 mL	40.6075 mL
5 mM	0.8121 mL	4.0607 mL	8.1215 mL
10 mM	0.4061 mL	2.0304 mL	4.0607 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献